New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 17, 2014
07:40 EDTNBSNeoStem reports fourth data safety monitoring board review of PreSERVE AMI trial
NeoStem announced that, on March 11, the Data Safety Monitoring Board, or DSMB, recommended continuing the PreSERVE AMI Phase 2 clinical trial following a fourth interim data and safety review. The PreSERVE trial of AMR-001 is a Phase 2, randomized, placebo controlled, double-blind study designed to enroll 160 patients. AMR-001 is being evaluated for the preservation of heart function after a severe heart attack. Full enrollment has been completed for the trial and data will be available in the second half of 2014. AMI, significantly reduces the cumulative incidence of major adverse clinical cardiac events, including death, heart failure and recurrent cardiac ischemia1. These data further support the ongoing development of NeoStem's lead product candidate, AMR-001, an autologous bone marrow derived CXCR4 expressing cell that was shown in a Phase 1 trial to induce new blood vessel growth and preserve heart muscle function after a severe heart attack.
News For NBS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 21, 2015
15:19 EDTNBSNeoStem spikes higher, levels to watch
The shares are spiking sharply, last up more than 45% to $3.30. At that price next resistance is at the session high at $3.47 and then at $3.71. Support is at $3.17.
15:17 EDTNBSNeoStem up over 40% after getting $17.7M grant for metastatic melanoma treatment
Subscribe for More Information
15:15 EDTNBSNeoStem gets $17.7M grant for metastatic melanoma treatment
Subscribe for More Information
15:11 EDTNBSNeoStem gets $17.7M grant from CIRM

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use